Both Biomedical Advanced Research and Development Authority (BARDA) and National Heart, Lung, and Blood Institute (NHLBI) have announced funding opportunities to advance research related to COVID-19.
Biomedical Advanced Research and Development Authority (BARDA), part of the HHS Office of the Assistant Secretary for Preparedness and Response, was established to aid in securing our nation from chemical, biological, radiological, and nuclear (CBRN) threats, as well as from pandemic influenza (PI) and emerging infectious diseases (EID). BARDA is soliciting proposals for the advanced research and development of medical countermeasures under the BARDA Broad Agency Announcement.
Proposals submitted under this BAA must focus on research and development activities that relate to specific areas of interest, consisting of medical countermeasures for chemical, biological, radiological and nuclear threats; pandemic influenza; and emerging infectious diseases. Due to the COVID-19 response, any white papers or full proposals submissions, other than those that are in support of COVID-19, will be put into a queue. Once the response to COVID-19 has subsided, we will resume normal review of submissions for other research areas of interests.
Submission in response to the BAA occurs in two stages. Stage 1 requires submitting a Quad Chart and White Paper; Stage 2 requires submitting a Full Proposal. Submission deadline is October 31, 2020.
Read the full announcement: https://beta.sam.gov/opp/1b46a4169fcb4902b9c4fcbb5bf981f7/view
In addition, National Heart, Lung, and Blood Institute (NHLBI) issued a Notice of Special Interest (NOSI) to highlight the urgent need for research on Coronavirus Disease 2019 (COVID-19) and on biological effects of its causative agent, the severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2). Topics of specific interest to NHLBI include host response, associations with heart, lung, and blood (HLB) diseases, potential impacts on transfusion safety, and clinical outcomes of infected individuals.
To better understand the host response, associated HLB disease, impact on transfusion safety, and short- and long-term clinical outcomes of individuals infected with SARS-CoV-2, the NHLBI encourages the submission of applications for Administrative Supplements and Competitive Revisions to active NHLBI grants to support research on SARS-CoV-2 and HLB COVID-19 disease. Of particular interest are studies that take advantage of human research or unique model systems to study the consequences of SARS-CoV-2 infection. Supported research is expected to inform future efforts to diagnose, prevent, mitigate, or treat this viral infection and associated HLB manifestations.
Applications will be accepted on a rolling basis from March 17, 2020 through October 5, 2020 by 5:00 PM local time of the applicant organization.
Read the full notice: NOT-HL-20-757